Detalhe da pesquisa
1.
Complement C3 is a novel modulator of the anti-factor VIII immune response.
Haematologica
; 103(2): 351-360, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146705
2.
Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.
EMBO J
; 28(16): 2469-78, 2009 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-19574954
3.
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
Blood
; 114(26): 5322-30, 2009 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19805620
4.
Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration.
Adv Exp Med Biol
; 703: 151-62, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20711713
5.
Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Toxicon
; 184: 68-77, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32526239
6.
Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Dev Comp Immunol
; 33(1): 105-16, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18760301
7.
Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Toxicon
; 167: 106-116, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207349
8.
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Adv Exp Med Biol
; 632: 293-307, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19025130
9.
Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Mol Immunol
; 97: 1-7, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29525557
10.
The Complement System in Neuropathic and Postoperative Pain.
Open Pain J
; 9: 26-37, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28154610
11.
Recombinant cobra venom factor.
Mol Immunol
; 41(2-3): 191-9, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15159065
12.
Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Thromb Haemost
; 113(3): 548-52, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25031089
13.
Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Mol Immunol
; 61(2): 191-203, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25062833
14.
Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Toxicon
; 60(4): 632-47, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22609532
15.
Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents.
Hawaii Med J
; 64(5): 133-4, 137, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15989147
16.
Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Toxicon
; 56(7): 1198-222, 2010 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20417224
17.
Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury.
Mol Immunol
; 47(2-3): 506-10, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19747734
18.
Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Curr Pharm Des
; 13(28): 2916-26, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17979736
19.
Structure and function of recombinant cobra venom factor.
J Biol Chem
; 279(29): 30836-43, 2004 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-15131128